Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

Figure 4

Dose-dependent inhibitory effects of RO9021 on osteoclastogenesis. (A) Representative images of tartrate-resistant acid phosphate (TRAP) staining showing receptor activator of nuclear factor kappa-B ligand (RANK-L) and monocyte colony-stimulating factor (M-CSF) mediated osteoclastogenesis from mouse bone marrow macrophages (BMM). Osteoclasts were shown as TRAP+ multinuclear cells. Negative and positive controls labeled as (–) RANK-L (upper left) and (+) RANK-L (upper right), respectively. The concentration of RO9021 was labeled on the upper right corner of each image. (B) TRAP+ multinuclear osteoclasts were counted under a microscope and percentage of inhibition on osteoclastogenesis was presented. Results were in triplicate and are plotted as mean ± standard deviation. IC50, half-maximal inhibitory concentration.

Back to article page